{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:54:15Z","timestamp":1784933655058,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Placenta"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.placenta.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T20:27:55Z","timestamp":1672777675000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8943-2269","authenticated-orcid":false,"given":"Natalie K.","family":"Binder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"de Alwis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Kadife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu'uhevaha J.","family":"Kaitu'u-Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona C.","family":"Brownfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2250","authenticated-orcid":false,"given":"Natalie J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5728","key":"10.1016\/j.placenta.2023.01.001_bib1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1126\/science.1111726","article-title":"Latest advances in understanding preeclampsia","volume":"308","author":"Redman","year":"2005","journal-title":"Science"},{"issue":"9461","key":"10.1016\/j.placenta.2023.01.001_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.placenta.2023.01.001_bib3","doi-asserted-by":"crossref","first-page":"287 e1","DOI":"10.1016\/j.ajog.2016.12.029","article-title":"Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta","volume":"216","author":"Labarrere","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.08.003","article-title":"Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity","volume":"213","author":"Redman","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.placenta.2023.01.001_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.placenta.2023.01.001_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semnephrol.2010.10.004","article-title":"Angiogenic factors and preeclampsia","volume":"31","author":"Maynard","year":"2011","journal-title":"Semin. Nephrol."},{"issue":"11","key":"10.1016\/j.placenta.2023.01.001_bib7","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1210\/en.2004-0533","article-title":"Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia","volume":"145","author":"Nagamatsu","year":"2004","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.placenta.2023.01.001_bib8","doi-asserted-by":"crossref","first-page":"782 e1","DOI":"10.1016\/j.ajog.2016.07.056","article-title":"In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies","volume":"215","author":"Holme","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.placenta.2023.01.001_bib9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nm1429","article-title":"Soluble endoglin contributes to the pathogenesis of preeclampsia","volume":"12","author":"Venkatesha","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.placenta.2023.01.001_bib10","doi-asserted-by":"crossref","first-page":"108 e1","DOI":"10.1016\/j.ajog.2015.09.066","article-title":"Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study","volume":"214","author":"Kim","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.placenta.2023.01.001_bib11","doi-asserted-by":"crossref","first-page":"212 e1","DOI":"10.1016\/j.ajog.2015.03.032","article-title":"Angiogenic markers in pregnancies conceived through in vitro fertilization","volume":"213","author":"Lee","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.placenta.2023.01.001_bib12","doi-asserted-by":"crossref","first-page":"636 e1","DOI":"10.1016\/j.ajog.2014.11.035","article-title":"Maternal circulating angiogenic factors in twin and singleton pregnancies","volume":"212","author":"Faupel-Badger","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"24","key":"10.1016\/j.placenta.2023.01.001_bib13","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1161\/CIRCULATIONAHA.109.853127","article-title":"Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease","volume":"123","author":"Powe","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.placenta.2023.01.001_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","article-title":"Pathogenesis of preeclampsia","volume":"5","author":"Young","year":"2010","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.placenta.2023.01.001_bib15","first-page":"466","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology, Nature reviews","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nephrology"},{"key":"10.1016\/j.placenta.2023.01.001_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/uog.17399","article-title":"Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks\u2019 gestation","volume":"49","author":"O\u2019Gorman","year":"2017","journal-title":"Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.placenta.2023.01.001_bib17","doi-asserted-by":"crossref","first-page":"544 e1","DOI":"10.1016\/j.ajog.2013.08.019","article-title":"Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease","volume":"209","author":"Lisonkova","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.placenta.2023.01.001_bib18","doi-asserted-by":"crossref","first-page":"476 e1","DOI":"10.1016\/j.ajog.2013.02.042","article-title":"The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008","volume":"208","author":"Thornton","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib19","doi-asserted-by":"crossref","first-page":"515 e1","DOI":"10.1016\/j.ajog.2014.10.1090","article-title":"Expectant management of mild preeclampsia versus superimposed preeclampsia up to 37 weeks","volume":"212","author":"Valent","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.placenta.2023.01.001_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.preghy.2020.07.013","article-title":"Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia","volume":"22","author":"Binder","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.placenta.2023.01.001_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","article-title":"Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction","volume":"41","author":"Brownfoot","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.placenta.2023.01.001_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.placenta.2020.04.010","article-title":"Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: implications for the treatment of preeclampsia","volume":"95","author":"Brownfoot","year":"2020","journal-title":"Placenta"},{"key":"10.1016\/j.placenta.2023.01.001_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.placenta.2019.09.004","article-title":"Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling","volume":"87","author":"Hastie","year":"2019","journal-title":"Placenta"},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.placenta.2023.01.001_bib25","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201517","article-title":"The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health","volume":"5","author":"de Alwis","year":"2022","journal-title":"Life Sci Alliance"},{"issue":"15","key":"10.1016\/j.placenta.2023.01.001_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158185","article-title":"Actions of esomeprazole on the maternal vasculature in lean and obese pregnant mice with impaired nitric oxide synthesis: a model of preeclampsia","volume":"23","author":"de Alwis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.placenta.2023.01.001_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ajh\/hpx130","article-title":"Tadalafil improves L-NG-nitroarginine methyl ester-induced preeclampsia with fetal growth restriction-like symptoms in pregnant mice","volume":"31","author":"Yoshikawa","year":"2017","journal-title":"Am. J. Hypertens."},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0366-6999.225058","article-title":"Different effects of pravastatin on preeclampsia-like symptoms in different mouse models","volume":"131","author":"Huai","year":"2018","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.placenta.2023.01.001_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12884-021-03650-7","article-title":"Vagus nerve stimulation ameliorates L-NAME-induced preeclampsia-like symptoms in rats through inhibition of the inflammatory response","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"issue":"10","key":"10.1016\/j.placenta.2023.01.001_bib30","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.placenta.2023.01.001_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026937","article-title":"Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study","volume":"6","author":"Weiler","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.placenta.2023.01.001_bib33","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1152\/ajpregu.00600.2011","article-title":"eNOS knockout mouse as a model of fetal growth restriction with an impaired uterine artery function and placental transport phenotype","volume":"303","author":"Kusinski","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.placenta.2023.01.001_bib34","series-title":"Interpretation of Animal Dose and Human Equivalent Dose for","author":"Shin","year":"2010"},{"issue":"3","key":"10.1016\/j.placenta.2023.01.001_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/rheumatology\/24.3.269","article-title":"Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy","volume":"24","author":"Pullar","year":"1985","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.placenta.2023.01.001_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2019.12.011","article-title":"Transcriptomic analysis reveals the mechanism of sulfasalazine-induced liver injury in mice","volume":"321","author":"Li","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"4","key":"10.1016\/j.placenta.2023.01.001_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/mutage\/gen005","article-title":"Radioprotective effect of sulfasalazine on mouse bone marrow chromosomes","volume":"23","author":"Mantena","year":"2008","journal-title":"Mutagenesis"}],"container-title":["Placenta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400423000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143400423000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T18:08:31Z","timestamp":1758910111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143400423000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"alternative-id":["S0143400423000012"],"URL":"https:\/\/doi.org\/10.1016\/j.placenta.2023.01.001","relation":{},"ISSN":["0143-4004"],"issn-type":[{"value":"0143-4004","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model","name":"articletitle","label":"Article Title"},{"value":"Placenta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.placenta.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}